Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mark Heinen Insider Profile
11 Followers
Mark Heinen, CFO at Better Therapeutics, Inc., holds 147.96K shares in Volato Group (Ticker: SOAR), holds 142.00K shares in Better Therapeutics, Inc. (Ticker: BTTX).
Profitable Transactions
0 out of 6 Profitable Transactions
Average Return
-61.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jun 28, 2022 - Jun 28, 2023
Return:-46.30%
The most profitable trade made by Mark Heinen
Mark Heinen's Trading History
Better Therapeutics, Inc.
Apr 21, 2023
CFO
Uninformative Buy
―
$1.42K
Volato Group
Jun 11, 2024
CFO
Uninformative Buy
―
$33.74K
List of latest transactions for each holding click on a transaction to see Mark Heinen's performance on stock
You May Also Like
Mark Heinen insider profile FAQ
What is the percentage of profitable transactions made by Mark Heinen?
The percentage of profitable transactions made by Mark Heinen is 0%.
What is the average return per transaction made by Mark Heinen?
The average return per transaction made by Mark Heinen is -61.60%.
What stocks does Mark Heinen hold?
Mark Heinen holds: BTTX, SOAR stocks.
What was Mark Heinen’s latest transaction?
Mark Heinen latest transaction was an Uninformative Buy of ―.
What was Mark Heinen's most profitable transaction?
Mark Heinen’s most profitable transaction was an Informative Buy of BTTX stock on June 28, 2022. The return on the trade was -46.30%.
What is Mark Heinen's role in Better Therapeutics, Inc.?
Mark Heinen's role in Better Therapeutics, Inc. is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.